Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 4.7%

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) traded down 4.7% during mid-day trading on Monday . The company traded as low as $13.09 and last traded at $13.09. 37,396 shares were traded during trading, a decline of 89% from the average session volume of 354,533 shares. The stock had previously closed at $13.73.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Truist Financial initiated coverage on shares of Y-mAbs Therapeutics in a research report on Friday, June 28th. They set a “buy” rating and a $21.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price target on shares of Y-mAbs Therapeutics in a report on Monday, September 9th. Canaccord Genuity Group upgraded shares of Y-mAbs Therapeutics to a “strong-buy” rating in a report on Tuesday, August 13th. Wedbush reiterated an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. Finally, BMO Capital Markets decreased their price target on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Y-mAbs Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $21.14.

Y-mAbs Therapeutics Trading Down 5.0 %

The stock’s 50 day moving average price is $12.86 and its 200 day moving average price is $13.41. The firm has a market cap of $572.23 million, a PE ratio of -26.94 and a beta of 0.70.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.08). The firm had revenue of $22.80 million for the quarter, compared to analysts’ expectations of $23.09 million. Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. During the same period last year, the firm earned ($0.14) EPS. Analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.57 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Joris Wilms sold 5,000 shares of Y-mAbs Therapeutics stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the transaction, the chief operating officer now directly owns 30,600 shares of the company’s stock, valued at approximately $449,514. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Y-mAbs Therapeutics news, insider Thomas Gad sold 30,000 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $12.97, for a total transaction of $389,100.00. Following the completion of the transaction, the insider now directly owns 67,681 shares of the company’s stock, valued at approximately $877,822.57. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Joris Wilms sold 5,000 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $14.69, for a total transaction of $73,450.00. Following the transaction, the chief operating officer now directly owns 30,600 shares of the company’s stock, valued at $449,514. The disclosure for this sale can be found here. Insiders sold a total of 100,000 shares of company stock valued at $1,338,100 in the last ninety days. Corporate insiders own 21.50% of the company’s stock.

Institutional Trading of Y-mAbs Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. raised its holdings in shares of Y-mAbs Therapeutics by 39.9% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock worth $60,000 after purchasing an additional 1,056 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Y-mAbs Therapeutics by 66.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 8,390 shares of the company’s stock valued at $136,000 after purchasing an additional 3,340 shares in the last quarter. XTX Topco Ltd purchased a new position in Y-mAbs Therapeutics during the second quarter valued at approximately $297,000. Caxton Associates LP purchased a new position in Y-mAbs Therapeutics during the first quarter valued at approximately $306,000. Finally, Price T Rowe Associates Inc. MD grew its position in Y-mAbs Therapeutics by 8.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock worth $345,000 after acquiring an additional 1,657 shares in the last quarter. 70.85% of the stock is currently owned by institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.